ISPC Company Profile and Key Details

ISPC has shown mixed momentum, gaining 8.24% over the past week and -54.78% over the past quarter, though year-to-date performance is up 28.8%. Short-term trend indicators are bullishly aligned (SMA20 -11.38%, SMA50 -17.6%, SMA200 -66.81%). The stock’s 14-day RSI is 41.27 (neutral), while the ATR of 0.04 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -91.35% below its high and over 19.46% above its low. Average 10-day trading volume of 421.13 thousand shares is below the 3-month average of 712.56 thousand, indicating normal recent market interest.

iSpecimen Inc. generated EPS of -$7.89 over the past year. Five-year average earnings growth is -4.07%. The latest quarter delivered EPS of -$23.60. The next quarter is forecast at $nan. Next year's EPS is expected at $17.86. iSpecimen Inc. earnings surprise history is a mixed track record. The quarter that ended April 01, 2026, missed forecasts by -84.47%. The prior quarter beat by -87.37%. Over the last six quarters, Apple has recorded several small beats. These include 1005.26% in November 07, 2024.

iSpecimen Inc. has 5.54 million shares outstanding. The public float is 5.50 million shares, elevated short interest at 5.82% of float. This equals 231.41 thousand shares. The short ratio is 0.83 days. Institutional investors hold 1.23% of the float. Insiders own 1.22%. Ross Andrew L. holds 1.31 million shares, Bielak Benjamin has 84.35 thousand shares and Curley Tracy has 49.54 thousand shares.

iSpecimen Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.97. This means the shares are trading below this model’s fair value.

iSpecimen Inc. (NASDAQ:ISPC) closed at $5.62 USD, gaining $0.39 (7.46%) from the previous close of $5.23. The stock is currently mid-range between its 52-week high and low $4.00 and $127.20. With a market capitalization of about $780.40 thousand, iSpecimen Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.98). Key stats such as the average daily volume over the past year has been around 907.53 thousand shares, trading with heavier-than-usual volume. Headquartered in Woburn, MA, iSpecimen Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Katharyn Field, the company employs approximately 24 people and listed since June 17, 2021. iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide.

iSpecimen Inc. trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 0.37 and a price-to-book ratio of 0.19 suggesting the stock is closer to book value. The P/FCF stands at -0.17, also below market averages.

iSpecimen Inc. (NASDAQ:ISPC) shares are up 28.8% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows iSpecimen Inc. trading at a premium to the broader market with a P/E of -0.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.25, suggesting -18.74% downside. Our AI forecast model points to short-term weakness (-34.42% over two weeks), a medium-term fall (-69.98% over three months), and a longer-term loss (-76.86% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that iSpecimen Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -34.42%, with price expected at $3.43 by May 14, 2026, within a range of $2.23 to $4.63 3-Month Outlook: Projected fall of -69.98%, reaching $1.57 by July 29, 2026, with a range of $0.00 to $4.19. 1-Year Outlook: Projected loss of -76.86%, with price at $1.21 by April 30, 2027, within a range of $0.00 to $11.94.